Arnaldi G, Angeli A, Atkinson AB, et al.Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602.
2.
Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484.
3.
Schuff KG. Issues in the diagnosis of Cushing’s syndrome for the primary care physician. Primary Care Clin Office Pract. 2003;30:4.
4.
Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing’s syndrome. Psychoneruoendocrinology. 2002;27:367-383.
5.
Williams RH, Larsen PR, Kronenberg HM, et al.Williams Textbook of Endocrinology, 10th ed.St. Louis: Elsevier, 2003.
6.
Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing’s syndrome after intraarticular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004;113:1820-1824.
7.
Allen DB, Bielory L, Derendorf H, et al.Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112:S1-S40.
8.
Ermis B, Ors R, Tastekin A, Ozkan B. Cushing’s syndrome secondary to topical corticosteroids abuse. Clin Endocrinol. 2003;58:795-796.
9.
Vermeer H, Hendriks-Stegeman BI, van der Burg B, et al.Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: A potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab. 2003;88:277-284.
10.
Murray L. Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 2001.
